Business
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"text","content":"Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen’s transferrin-receptor targeting Enhanced Brain Delivery (EBD™) programCandidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcutaneous administrationLead clinical candidate IND targeted for mid-2027 NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses. “This financing from committed institutional investors strongly validates our portfolio and our Enhanced Brain Delivery strategy,” said Daniel O’Connell, Chief Executive Officer of Acumen. “The transaction also underscores confidence in the potential value we are building with amyloid β oligomer-targeted antibodies for Alzheimer’s patients, caregivers and stakeholders in alignment with Acumen’s vision.” The private placement was led by existing investor RA Capital Management, with participation from other investors, including ADAR1 Capital Management, Sands Capital, and a large investment management firm. The private placement is expected to close on or about March 16, 2026, subject to the satisfaction of customary closing conditions. Proceeds from the financing are expected to primarily support Acumen’s Enhanced Brain Delivery (EBD) program, including ongoing preclinical development work to support the nomination of a lead clinical candidate molecule, and for working capital and other general corporate purposes. Submission of an IND with respect to a lead clinical candidate is targeted for mid-2027. The securities to be ...